Search results for "Cholesterol"

showing 10 items of 1211 documents

Variations in maximal oxygen intake with physical activity in middle-aged men.

1970

Data on maximal exercise performance are presented for normal middle-aged men free of cardiovascular disease. Maximal oxygen intake, oxygen pulse, heart rate, and lactate levels all decrease with increasing age. Physical activity defined by habitual running of any amount had a highly significant effect on maximal oxygen consumption. The enhanced effect of physical activity was found equivalent to nearly 10 years of age effect on maximal aerobic capacity. Multivariate analysis revealed significant association between maximal oxygen intake and several coronary risk factors; specifically, physical activity, vital capacity, cigarette smoking, and body weight. Notably lacking in significance wer…

AdultMalemedicine.medical_specialtyPhysical ExertionVital CapacityOxygen pulsePhysical activityPhysiologychemistry.chemical_elementBlood PressureOxygenchemistry.chemical_compoundOxygen ConsumptionCigarette smokingHeart RatePhysiology (medical)Heart ratemedicineHumansAgedCholesterolbusiness.industryBody WeightSmokingAge FactorsVO2 maxMiddle AgedBlood pressureCholesterolchemistryPhysical therapyLactatesCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Association of metabolic syndrome and its components with hyperuricemia in a Mediterranean population.

2015

Several studies have found an association between hyperuricemia and metabolic syndrome (MS), although there are discrepancies as to which MS components play a pivotal role in this association. We aimed to investigate the association between serum uric acid (SUA) levels and MS in a Mediterranean population (eastern Spain). We performed a case-control study of 71 patients with MS and 122 healthy controls. MS was defined according to the revised National Cholesterol Education Program Adult Treatment Panel III modified criteria. Hyperuricemia was defined as SUA levels >6.55 mg/dL. We determined biochemical, lipidic and inflammatory parameters along with uric acid. Patients with MS showed a high…

AdultMalemedicine.medical_specialtyPhysiologyPopulationHyperuricemiaLogistic regressionGastroenterologychemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumansHyperuricemiaeducationNational Cholesterol Education ProgramAbdominal obesityMetabolic Syndromeeducation.field_of_studybusiness.industryMediterranean RegionHypertriglyceridemianutritional and metabolic diseasesHematologyMiddle Agedmedicine.diseaseEndocrinologychemistrySpainCase-Control StudiesUric acidFemaleMetabolic syndromemedicine.symptomCardiology and Cardiovascular MedicinebusinessClinical hemorheology and microcirculation
researchProduct

Oxidative stress and maternal obesity: Feto-placental unit interaction

2013

Abstract Objective To determine oxidative stress markers in maternal obesity during pregnancy and to evaluate feto-placental unit interaction, especially predictors of fetal metabolic alterations. Patients and methods 40 obese pregnant women (prepregnancy BMI > 30 kg/m²) were compared to 50 control pregnant women. Maternal, cord blood and placenta samples were collected at delivery. Biochemical parameters (total cholesterol and triglycerides) and oxidative stress markers (malondialdehyde, carbonyl proteins, superoxide anion expressed as reduced Nitroblue Tetrazolium, nitric oxide expressed as nitrite, reduced glutathione, catalase, superoxide dismutase) were assayed by biochemical methods. …

AdultMalemedicine.medical_specialtyPlacentaNitric Oxidemedicine.disease_causeNitric oxideSuperoxide dismutasechemistry.chemical_compoundPregnancySuperoxidesMalondialdehydeInternal medicinePlacentamedicineHumansObesityMaternal-Fetal ExchangeTriglyceridesFetusPregnancybiologySuperoxide DismutaseSuperoxidebusiness.industryInfant NewbornProteinsObstetrics and GynecologyBlood ProteinsCatalaseFetal Bloodmedicine.diseaseMalondialdehydeGlutathionePregnancy ComplicationsOxidative StressCholesterolEndocrinologymedicine.anatomical_structureReproductive Medicinechemistrybiology.proteinFemalebusinessOxidation-ReductionBiomarkersOxidative stressDevelopmental BiologyPlacenta
researchProduct

Adverse Cardiovascular Response to Aerobic Exercise Training

2015

AB Purpose: Aerobic exercise training in sedentary individuals improves physical fitness and various cardiovascular (CV) biomarkers. Nevertheless, there has been controversy as to whether exercise training may adversely affect some biomarkers in a small segment of the population. The purpose of this study was to investigate whether clinically significant worsening of CV biomarkers was more prevalent among individuals randomized to a supervised endurance training program as compared with those randomized to a control condition. Methods: Baseline and end of study measurements of fasting insulin (FI), triglycerides (TG), resting systolic blood pressure (SBP), and HDL cholesterol (HDL-C) were o…

AdultMalemedicine.medical_specialtyPopulationPhysical fitnessBlood PressurePhysical Therapy Sports Therapy and RehabilitationArticlelaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialEndurance traininglawInternal medicinemedicineta319cardiovascular reponseHumansInsulinAerobic exerciseOrthopedics and Sports Medicine030212 general & internal medicineExercise physiologyta315educationExerciseTriglyceridesAgededucation.field_of_studyPhysical Education and TrainingCholesterolbusiness.industryCholesterol HDL030229 sport sciencesMiddle AgedBlood pressurechemistryPhysical Fitnessaerobic exercise trainingPhysical therapyCardiologyFemalebusinessBiomarkersMedicine & Science in Sports & Exercise
researchProduct

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.

2013

This randomized open-label study compared the incidence of metabolic side effects of aripiprazole, ziprasidone and quetiapine in a population of medication-naive first-episode psychosis patients. A total of 202 subjects were enrolled. Body weight, body mass index, leptin, fasting lipids and fasting glycaemic parameters were measured at baseline and at 3 months follow-up. A hundred and sixty-six patients completed the follow-up and were included in the analyses. A high proportion of patients experienced a significant weight increase (>7% of their baseline weight): 23% ziprasidone (n=12), 32% with quetiapine (n=16) and 45% with aripiprazole (n=31). Patients treated with aripiprazole gained si…

AdultMalemedicine.medical_specialtyPsychosisDibenzothiazepinesPopulationAripiprazoleQuinolonesWeight GainGastroenterologyPiperazinesQuetiapine FumarateSex FactorsInternal medicinemedicineHumansZiprasidoneeducationPsychiatryBiological Psychiatryeducation.field_of_studybusiness.industryLeptinmedicine.diseaseProlactinPsychiatry and Mental healthThiazolesCholesterolPsychotic DisordersQuetiapineAripiprazoleFemalemedicine.symptombusinessWeight gainBody mass indexmedicine.drugAntipsychotic AgentsFollow-Up StudiesSchizophrenia research
researchProduct

Quantification of epicardial fat with cardiac CT angiography and association with cardiovascular risk factors in symptomatic patients: From the ALTER…

2019

PURPOSE We aimed to assess the association between features of epicardial adipose tissue and demographic, morphometric and clinical data, in a large population of symptomatic patients with clinical indication to cardiac computed tomography (CT) angiography. METHODS Epicardial fat volume (EFV) and adipose CT density of 1379 patients undergoing cardiac CT angiography (918 men, 66.6%; age range, 18–93 years; median age, 64 years) were semi-automatically quantified. Clinical variables were compared between diabetic and nondiabetic patients to assess potential differences in EFV and adipose CT density. Multiple regression models were calculated to find the clinical variables with a significant a…

AdultMalemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingComputed Tomography AngiographyHypercholesterolemiaAdipose tissue030218 nuclear medicine & medical imagingBody Mass Index03 medical and health sciences0302 clinical medicineRisk FactorsRetrospective StudieInternal medicineDiabetes mellitusCardiovascular DiseaseDiabetes MellitusmedicineHumansPericardiumCardiovascular ImagingRetrospective StudiesComputed tomography angiographyAgedAged 80 and overmedicine.diagnostic_testbusiness.industryRisk FactorRetrospective cohort studyDiabetes MellituBiomarkerMiddle Agedmedicine.diseaseEpicardial fatmedicine.anatomical_structureAdipose TissueCardiovascular DiseasesAngiographyHypertensionCardiologyFemalebusinessCardiology and Cardiovascular MedicineBody mass indexPericardiumBiomarkersHuman
researchProduct

A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia

2013

Objective— In familial hypobetalipoproteinemia, fatty liver is a characteristic feature, and there are several reports of associated cirrhosis and hepatocarcinoma. We investigated a large kindred in which low-density lipoprotein cholesterol, fatty liver, and hepatocarcinoma displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 25-year-old female with low plasma cholesterol and hepatic steatosis. Low plasma levels of total cholesterol and fatty liver were observed in 10 more family members; 1 member was affected by liver cirrhosis, and 4 more subjects died of either hepatocarcinoma or carcinoma on cirrhosis. To identify the causal mutation in this f…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BNonsense mutationBiologyArticlehypobetaliproteinemia type 1Hypobetalipoproteinemiasexome fatty liver hypobetalipoproteinemia familial 2Young Adultsymbols.namesakeInternal medicinemedicineHumansExomeHEPATOCELLULAR CARCINOMAExomeExome sequencingApolipoproteins Bfatty liverFamily HealthGeneticsSanger sequencingLiver NeoplasmsFatty liverMiddle AgedHEPATOCELLULAR CARCINOMA; exome; fatty liver; hypobetaliproteinemia type 1medicine.diseasePedigreeFatty LiverHypocholesterolemiaCholesterolEndocrinologyCodon Nonsensebiology.proteinsymbolsFemaleCardiology and Cardiovascular MedicineLiver cancerexomeArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholeste…

2017

Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression.1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins. In a pivotal 78-week open-label trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia.2 The principal …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BSocio-culturaleFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologyMicrosomal triglyceride transfer proteinLDLTimeSudden cardiac deathHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineAdverse effectlomitapidebiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLlomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Carrier Proteins; Cholesterol LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Timemedicine.diseaseLomitapideCholesterolEndocrinologychemistrybiology.proteinBenzimidazolesFemalelipids (amino acids peptides and proteins)lomitapide; Cardiology and Cardiovascular Medicine; Physiology (medical)Carrier ProteinsCardiology and Cardiovascular MedicinebusinessLipoproteinCirculation
researchProduct

Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis.

2006

Objective: The aim of the study is to evaluate the effect of moderate Sicilian red wine consumption on cardiovascular risk factors and, in particular, on some inflammatory biomarkers. Methods: A total of 48 subjects of both sexes who were nondrinkers or rare drinkers of moderate red wine were selected and randomly subdivided into two groups assigned to receive with a crossover design a Sicilian red wine (Nero d’Avola or Etna Torrepalino) during meals: Group A (n ¼ 24), in whom the diet was supplemented for 4 weeks with 250 ml/day of red wine, followed by 4 weeks when they returned to their usual wine intake; and Group B (n ¼ 24), in whom the usual wine intake was maintained for 4 weeks, fol…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaMediterranean dietMedicine (miscellaneous)WineClinical nutritionFibrinogenDiet Mediterraneanchemistry.chemical_compoundRisk FactorsMediterranean dietInternal medicinemedicineHumansRisk factorAgedWineNutrition and DieteticsCross-Over StudiesFactor VIIbusiness.industryVascular diseasefood and beveragesred wineMiddle Agedmedicine.diseaseAtherosclerosisLipid MetabolismSettore MED/11 - Malattie Dell'Apparato CardiovascolareCrossover studySurgeryhs-CRPEndocrinologyC-Reactive ProteinCholesterolrisk factorchemistryItalyTGFb1red wine; risk factors; TGFb1; hs-CRP; Mediterranean dietFemaleInflammation MediatorsbusinessOxidation-ReductionBiomarkersmedicine.drugEuropean journal of clinical nutrition
researchProduct

Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.

2014

The microsomal triglyceride transfer protein (MTP) inhibitor lomitapide is a licenced adjunct to a low-fat diet and other lipid-lowering medication, with or without low-density lipoprotein apheresis, for the treatment of adults with homozygous familial hypercholesterolaemia (HoFH). In a recently published phase 3 study, patients with HoFH received lomitapide in addition to maximally tolerated lipid-lowering therapy. Treatment with lomitapide resulted in a mean approximate 50% reduction in LDL-C levels after 26 weeks compared with baseline levels (p < 0.0001). This decrease in LDL-C was maintained at Weeks 56 and 78 (44% [p < 0.0001] and 38% [p = 0.0001], respectively). This paper offers cli…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaPhases of clinical researchMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundYoung AdultInternal medicineHo-FH lomitapide MTPInternal MedicinemedicineEffective treatmentHumansIn patientAdverse effectbiologymedicine.diagnostic_testbusiness.industryAnticholesteremic AgentsHomozygoteGeneral MedicineCholesterol LDLMiddle AgedLomitapideEndocrinologyApheresisTreatment Outcomechemistrybiology.proteinBenzimidazolesFemaleCardiology and Cardiovascular MedicinebusinessLiver function testsAtherosclerosis. Supplements
researchProduct